Cryoport (CYRX) Osake Kurssi

The main competitors of Cryoport Inc in the market include World Courier, Marken, and DHL Life Sciences.

The business model of Cryoport Inc revolves around providing temperature-controlled logistics solutions for the life sciences industry. Cryoport specializes in the transportation of highly valuable and sensitive biologic materials, including cell and gene therapies, reproductive cells, and vaccines. By leveraging their advanced cryogenic frozen shipping technology and digital monitoring systems, Cryoport ensures the safe and efficient transportation of these materials within a strict temperature range. With their global network of logistics partners and state-of-the-art facilities, Cryoport offers end-to-end cold chain solutions, allowing companies to ship their products across the world while maintaining their integrity and efficacy.

Cryoport Inc is a leading provider of temperature-controlled logistics solutions for the life sciences industry. Founded in 1999, the company has established itself as a trusted partner for the safe, secure, and reliable transportation of critical biological materials, including cell therapies, gene therapies, and reproductive tissues. Cryoport's advanced cryogenic shipping solutions and cloud-based logistics platform have revolutionized the way these sensitive materials are transported. With a strong focus on innovation and customer satisfaction, Cryoport has rapidly expanded its global footprint, serving biopharmaceutical companies, CROs, and academic institutions worldwide. As a trusted name in the industry, Cryoport continues to play a vital role in facilitating the advancement of life-saving therapies.

Cryoport Inc has achieved several significant milestones in its operations. One noteworthy milestone is the company's expansion of its global footprint, enabling it to provide its temperature-controlled logistics solutions to clients across the world. Additionally, Cryoport has established strategic partnerships with leading pharmaceutical and biotech companies, solidifying its position as a trusted provider in the life sciences industry. The company has also been recognized for its innovative technology and services, receiving multiple awards and accolades for its contributions to cold chain logistics. Overall, Cryoport Inc continues to demonstrate success and growth in its mission to ensure the safe transport of valuable biopharmaceuticals worldwide.

Cryoport Inc is primarily present in various countries and regions worldwide. This includes the United States, Europe, Asia, and other parts of the world.

Cryoport Inc represents a strong commitment to ensuring the safe and efficient transportation of temperature-sensitive products, particularly in the life sciences and healthcare industries. With a focus on providing innovative logistics solutions, Cryoport leverages advanced packaging and monitoring technologies to maintain the integrity of biologic materials during transit. The company's corporate philosophy centers around reliability, quality, and customer satisfaction, aiming to meet the evolving needs of its clients while adhering to stringent regulatory requirements. By offering specialized cryogenic logistics services, Cryoport Inc enables companies to overcome the challenges of transporting vital, high-value biopharmaceuticals and other temperature-sensitive products worldwide.

Analyytikot asettavat tällä hetkellä Cryoport-osakkeelle keskimääräisen tavoitehinnan 18,79 USD (mediaani: 19,00 USD), mikä merkitsee +11,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.

Cryoport Analyytikkojen kursstavoitteet 2026

16 analyytikkoa arvioi tällä hetkellä Cryoport-osaketta: 14 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Cryoport-yhtiöltä 195,48 M USD liikevaihtoa ja −0,78 USD osakekohtaista tulosta.

Cryoport Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Cryoport-osake noteerataan hintaan 15,08 EUR (16,90 USD).

Cryoport-osake (CYRX) on listattuna 4 pörssissä, muun muassa: NASDAQ (CYRX), Frankfurt (CKX.F), München (CKX.MU), Düsseldorf (CKX.DU).

Cryoport Inc is a leading company in the field of biopharmaceutical cold chain logistics and offers innovative solutions for the transportation of sensitive and vital biological materials. The company was founded in 1999 and is headquartered in Irvine, California. Cryoport Inc serves over 500 pharmaceutical, biotechnology, and clinical trial customers worldwide. The business model of Cryoport Inc includes multiple divisions and products that are specifically designed to meet the requirements of sensitive experimental materials and clinical products. One of Cryoport Inc's most important products is CryoportalTM, a web-based customer portal that allows customers to manage shipments, place orders, and track shipments in real-time. Cryoport Inc also operates a 24/7 customer portal with real-time support from a dedicated customer service team. Additionally, they offer the Cryoport Express Shipping SystemTM, which utilizes the latest cold chain logistics technology to ensure a reliable, secure, and controlled temperature environment during transportation. Cryoport Inc also offers dry shippers and top-loading cryogenic containers that are specifically designed for the transportation of frozen biological materials. Another interesting offering from Cryoport Inc includes customs services. Alongside their own team of customs specialists, Cryoport Inc also handles import and export customs clearance. Cryoport Inc also provides a wide range of clinical and commercial biologics logistics solutions, applicable to the delivery of therapeutics and clinical products as well as clinical trial logistics. Overall, Cryoport Inc can provide its customers with a complete cold chain logistics infrastructure and professional support from experts in clinical trial logistics projects. Cryoport Inc's business model is based on avoiding material losses and successful clinical trials, as well as monitoring and managing all transportation processes of biological materials. Customers of Cryoport Inc can also rely on the latest advancements in temperature-controlled logistics, specifically the use of cryogenic containers and troczen loads, to improve the quality of their supply chains and logistics processes, as well as the delivery times of their products. In summary, Cryoport Inc possesses a strong business model due to its broad product offering, innovative technologies, and global presence, allowing the company to operate successfully in the cold chain logistics industry. Cryoport Inc is constantly striving to improve its offerings and services in order to best meet the needs of its customers in the sensitive and fast-paced pharmaceutical industry.

odotettu liikevaihto Cryoport on 195,48 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cryoport on −38,90 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cryoport:n hinta-voitto-suhde (P/E) on tällä hetkellä −21,62. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cryoport-osakkeen arvostusta.

Cryoport:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,30. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cryoport-osakkeen arvostuskennuslukuna.

Cryoport:n Eulpool-laatuscore on 3/10.

Cryoport:n ISIN on US2290503075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cryoport:n WKN on A14THD. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cryoport:n ticker on CYRX. Tämä pörssinoteeraus käytetään Cryoport-osakkeiden kauppaan pörssissä.